Abstract
Introduction
Severe asthma involves a persistent inflammation of the airways that is associated with a greater risk of exacerbations. Exacerbations are associated with a higher lung function decline over time. The prevention of lung function decline could become a strategy for disease modification, and this could be more likely to happen in patients with an earlier therapeutic approach. Thus, this study means to analyse the effect of asthma duration in clinical outcomes such as lung function in patients from the REDES study. REDES was an observational real-world study that assessed the effectiveness and safety of mepolizumab 100?mg s.c. every 4?weeks for 12?months in 318 patients with severe asthma in Spain.
Methods
This post hoc analysis evaluated how disease duration affected the study results through a stratification according to quartiles on their disease progression. Continuous analyses were also performed to assess the impact of confounder variables on forced expiratory volume in 1?s (FEV1) (%).
Results
At baseline, patients with shorter time of disease had a significantly higher lung function than patients with longer asthma duration. At 12?months, pre-bronchodilator (BD) FEV1 values and the proportion of patients with ?80% pre-BD FEV1 were higher according to a shorter disease persistence (Q1>Q2>Q3>Q4).
Conclusion
These results support that time of disease persistence contributes to the lung function decline of patients with severe asthma, uncontrolled while on previous treatment, and that an earlier approach with mepolizumab may imply a higher preservation of their lung function.
